Ocu­gen hits an­oth­er snag in bring­ing its Bharat Biotech-part­nered Covid-19 vac­cine to the US

4 years ago
FDA+
Coronavirus

Covid-19 roundup: As Omi­cron spreads, African biotech re­port­ed­ly close to re­pro­duc­ing Mod­er­na's vac­cine, while WHO ...

4 years ago
Coronavirus

Till­man Gern­gross on Omi­cron: 'It is a grim sit­u­a­tion...we’re go­ing to see a sig­nif­i­cant drop in vac­cine ef­fi­ca­cy'

4 years ago

HotSpot gets hot­ter with $100M raise to push to­ward clin­ic

4 years ago
Financing

Thanks­giv­ing edi­tion: Top 15 End­points sto­ries of 2021; Can you name that vac­cine?; Mer­ck­'s Covid an­tivi­ral ...

4 years ago
Weekly

Mer­ck shares slide as re­sponse to its oral Covid an­tivi­ral plunges on lat­est up­date ahead of ad­comm

4 years ago
FDA+

What were End­points read­ers tun­ing in­to this year? Here’s a look at our 15 most pop­u­lar re­ports of the year (so ...

4 years ago
Bioregnum
Cell/Gene Tx

Omi­cron: Re­searchers scram­ble as new coro­n­avirus mu­ta­tion takes flight around the globe — Pfiz­er/BioN­Tech, Mod­er­na ...

4 years ago
Coronavirus

BD an­nounces an­oth­er ex­pan­sion, this time in San Diego

4 years ago
R&D

Covid-19 roundup: Pfiz­er sues for­mer em­ploy­ee for steal­ing vac­cine se­crets; Eu­ro­pean of­fi­cials rec­om­mend vac­cine ...

4 years ago
Coronavirus

FDA com­mish nom­i­nee's fi­nan­cial dis­clo­sures re­veal a vast web of in­dus­try ties. Will they mat­ter?

4 years ago
People
FDA+

FDA asks court for 55 years to com­plete a FOIA re­quest on the Pfiz­er/BioN­Tech vac­cine

4 years ago
FDA+

FDA hits the red light on an ear­ly-stage AML study af­ter a pa­tient dies

4 years ago
R&D
FDA+

Eu­rope changes its tune on Covid-19 vac­cine IP, ad­vo­cat­ing now for a 'tar­get­ed waiver'

4 years ago
Pharma
Coronavirus

The deal for BeiGene's mas­sive new US man­u­fac­tur­ing and R&D site is com­plete, and it plans to pour in 'sev­er­al ...

4 years ago
Manufacturing

Af­ter a rocky decades-long jour­ney, Take­da’s CMV drug gets FDA OK

4 years ago
FDA+

Mer­ck­'s pause on an HIV pro­gram snow­balls as a Gilead-part­nered tri­al is shoved in­to lim­bo

4 years ago
Deals
R&D

BeiGene gets the ball rolling on its 3rd IPO — and this one is ex­pect­ed to fetch $3B

4 years ago
Financing
China

Tak­ing a leave of ab­sence, Am­pio Phar­ma­ceu­ti­cals CEO pass­es ba­ton to a new board mem­ber; Ax­el Hoos' can­cer biotech ...

4 years ago
Peer Review

Mar­ket­ingRx roundup: Am­gen, Lil­ly, Bio­haven mi­graine brand re­call low, study says; No­var­tis looks to re­make drug ...

4 years ago
Pharma
Marketing

Q&A: Hori­zon CEO Tim Wal­bert goes from C-suite to face of the brand

4 years ago
People
Pharma

Ho­log­ic part­ners with Black women ad­vo­cates on uter­ine fi­broids cam­paign to im­prove di­ag­noses and treat­ment

4 years ago
Pharma
Marketing

J&J’s neu­ro­science re­nais­sance? Janssen R&D chief ready­ing for 'gold­en age'

4 years ago
R&D
Pharma

Drag­on­fly gets Mer­ck on sec­ond TriN­KET can­di­date since 2018 col­lab; Chi­nese eye gene ther­a­py de­vel­op­er nabs $60M

4 years ago
News Briefing
First page Previous page 609610611612613614615 Next page Last page
A service from the Financial Times